Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Restructuring (2016)

Harvard Bioscience (HBIO) has disclosed Cash from Restructuring for 6 consecutive years, with -$27000.0 as the latest value for Q3 2016.

  • On a quarterly basis, Cash from Restructuring fell 80.0% to -$27000.0 in Q3 2016 year-over-year; TTM through Dec 2017 was -$27000.0, a 0.0% change, with the full-year FY2016 number at -$27000.0, up 68.24% from a year prior.
  • Cash from Restructuring was -$27000.0 for Q3 2016 at Harvard Bioscience, down from -$6000.0 in the prior quarter.
  • In the past five years, Cash from Restructuring ranged from a high of $95000.0 in Q3 2013 to a low of -$102000.0 in Q1 2014.
  • A 4-year average of -$25272.7 and a median of -$21000.0 in 2013 define the central range for Cash from Restructuring.
  • Peak YoY movement for Cash from Restructuring: surged 30.43% in 2014, then crashed 650.0% in 2015.
  • Harvard Bioscience's Cash from Restructuring stood at -$97000.0 in 2013, then skyrocketed by 97.94% to -$2000.0 in 2014, then crashed by 200.0% to -$6000.0 in 2015, then crashed by 350.0% to -$27000.0 in 2016.
  • Per Business Quant, the three most recent readings for HBIO's Cash from Restructuring are -$27000.0 (Q3 2016), -$6000.0 (Q4 2015), and -$15000.0 (Q3 2015).